Products - Endometrial cancers | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 April 2025
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2025
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC